Pfizer has agreed to pay $59.7m to resolve illegal payments to healthcare professionals made by Biohaven Pharmaceuticals, a biopharma it acquired over two years ago. The charges allege that ...

Pfizer (NYSE:PFE) has agreed to pay nearly $60M to resolve allegations that its Biohaven unit paid kickbacks to physicians to induce prescriptions for its migraine drug Nurtec ODT.

Pfizer has agreed to pay $59.75 million to settle claims that Biohaven Pharmaceutical Holding Co., which it acquired in 2022, defrauded Medicare and other healthcare programs by paying kickbacks ...

Pfizer subsidiary Biohaven allegedly gave physicians speaker honoraria and meals at high-end restaurants to induce them to prescribe Nurtec. A complete guide to lease accounting for healthcare ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter ...

The scheme took place from March 1, 2020, through Sept. 30, 2022. Pfizer bought Biohaven in October 2022. PFIZER'S PAXLOVID FAILS AS 15-DAY TREATMENT FOR LONG COVID, STUDY FINDS Prosecutors said ...

Pfizer PFE0.17%increase; green up pointing triangle will pay $60 million to settle allegations that one of its subsidiaries incentivized healthcare providers to prescribe one of its drugs ...

Pfizer, on behalf of its subsidiary Biohaven Pharmaceutical Holding Company, agreed to pay $59,746,277 to resolve allegations that prior to Pfizer’s acquisition, Biohaven paid kickbacks to physicians ...

Not content with a $1.2 billion licensing deal for Biohaven Pharma's oral migraine therapy rimegepant, Pfizer has just offered to buy the company outright – for a cool $11.6 billion. Pfizer's ...

The scheme took place from March 1, 2020, through Sept. 30, 2022. Pfizer bought Biohaven in October 2022. Prosecutors said that certain prescribers who attended multiple speaker programs on the ...